Ausgabe 10/2016
Inhalt (10 Artikel)
Performance-Based Agreements in Italy: ‘Trendy Outcomes’ or Mere Illusions?
Livio Garattini, Alessandro Curto
Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence
Alexis Llewellyn, Rita Faria, Beth Woods, Mark Simmonds, James Lomas, Nerys Woolacott, Susan Griffin
EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes
Mark Oppe, Kim Rand-Hendriksen, Koonal Shah, Juan M. Ramos‐Goñi, Nan Luo
The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan
Haruhisa Fukuda, Shunya Ikeda, Takeru Shiroiwa, Takashi Fukuda
Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3
Ron D. Hays, Dennis A. Revicki, David Feeny, Peter Fayers, Karen L. Spritzer, David Cella
A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy
Paul Tappenden, Shijie Ren, Rachel Archer, Rebecca Harvey, Marrissa Martyn-St James, Hasan Basarir, John Stevens, Alan Lobo, Sami Hoque
Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer
Bonny Parkinson, Rosalie Viney, Marion Haas, Stephen Goodall, Preeyaporn Srasuebkul, Sallie-Anne Pearson
BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles
William C. N. Dunlop, C. Daniel Mullins, Olaf Pirk, Ron Goeree, Maarten J. Postma, Ashley Enstone, Louise Heron
Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?
T. Joseph Mattingly II, C. Daniel Mullins, Eberechukwu Onukwugha